Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what the timetable is for the National Institute for Health and Care Excellence evaluation of the Duchenne muscular dystrophy treatment Exondys 51.

The National Institute for Health and Care Excellence (NICE) is developing guidance on the use of eteplirsen (Exondys 51) through its highly specialised technology (HST) evaluation programme. NICE’s HST evaluation committee is scheduled to discuss this topic in May 2018 with final guidance expected to be issued in October 2018. The provisional timeline for eteplirsen is based upon the anticipated licensing dates for the drug.